Prolactin-lowering effect of luteinizing hormone-releasing hormone agonist administration in prolactinoma patients

M. A. Rubio, J. A. Cabranes, Andrew V Schally, A. L. Charro

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We studied the effect of LHRH agonist administration on serum PRL levels in five women with microprolactinomas and two women and a man with intrasellar macroprolactinomas. Each patient received either D-Trp6-LHRH or buserelin for 90 days. Serum PRL levels decreased significantly in the patients with microprolactinomas by 65%, from 156 ± 93 (± SD) to 54 ± 49 μg/L on day 90 (P = 0.011), but it did not decrease in the macroprolactinoma patients. Mean serum LH and FSH decreased by 43% and 62.5%, respectively, in all eight patients. There was no statistically significant correlation between the serum PRL and LH or FSH levels in the microprolactinoma patients. We conclude that LHRH agonists can counteract the hyperprolactinemia produced by microprolactinomas and that the effect probably is not exerted by an action on the gonadotrophs.

Original languageEnglish
Pages (from-to)444-447
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume69
Issue number2
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Prolactinoma
Gonadotropin-Releasing Hormone
Prolactin
Buserelin
Serum
Gonadotrophs
Hyperprolactinemia

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Prolactin-lowering effect of luteinizing hormone-releasing hormone agonist administration in prolactinoma patients. / Rubio, M. A.; Cabranes, J. A.; Schally, Andrew V; Charro, A. L.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 69, No. 2, 01.01.1989, p. 444-447.

Research output: Contribution to journalArticle

@article{2563164b05ba40f599cd39f469039129,
title = "Prolactin-lowering effect of luteinizing hormone-releasing hormone agonist administration in prolactinoma patients",
abstract = "We studied the effect of LHRH agonist administration on serum PRL levels in five women with microprolactinomas and two women and a man with intrasellar macroprolactinomas. Each patient received either D-Trp6-LHRH or buserelin for 90 days. Serum PRL levels decreased significantly in the patients with microprolactinomas by 65{\%}, from 156 ± 93 (± SD) to 54 ± 49 μg/L on day 90 (P = 0.011), but it did not decrease in the macroprolactinoma patients. Mean serum LH and FSH decreased by 43{\%} and 62.5{\%}, respectively, in all eight patients. There was no statistically significant correlation between the serum PRL and LH or FSH levels in the microprolactinoma patients. We conclude that LHRH agonists can counteract the hyperprolactinemia produced by microprolactinomas and that the effect probably is not exerted by an action on the gonadotrophs.",
author = "Rubio, {M. A.} and Cabranes, {J. A.} and Schally, {Andrew V} and Charro, {A. L.}",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "69",
pages = "444--447",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Prolactin-lowering effect of luteinizing hormone-releasing hormone agonist administration in prolactinoma patients

AU - Rubio, M. A.

AU - Cabranes, J. A.

AU - Schally, Andrew V

AU - Charro, A. L.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - We studied the effect of LHRH agonist administration on serum PRL levels in five women with microprolactinomas and two women and a man with intrasellar macroprolactinomas. Each patient received either D-Trp6-LHRH or buserelin for 90 days. Serum PRL levels decreased significantly in the patients with microprolactinomas by 65%, from 156 ± 93 (± SD) to 54 ± 49 μg/L on day 90 (P = 0.011), but it did not decrease in the macroprolactinoma patients. Mean serum LH and FSH decreased by 43% and 62.5%, respectively, in all eight patients. There was no statistically significant correlation between the serum PRL and LH or FSH levels in the microprolactinoma patients. We conclude that LHRH agonists can counteract the hyperprolactinemia produced by microprolactinomas and that the effect probably is not exerted by an action on the gonadotrophs.

AB - We studied the effect of LHRH agonist administration on serum PRL levels in five women with microprolactinomas and two women and a man with intrasellar macroprolactinomas. Each patient received either D-Trp6-LHRH or buserelin for 90 days. Serum PRL levels decreased significantly in the patients with microprolactinomas by 65%, from 156 ± 93 (± SD) to 54 ± 49 μg/L on day 90 (P = 0.011), but it did not decrease in the macroprolactinoma patients. Mean serum LH and FSH decreased by 43% and 62.5%, respectively, in all eight patients. There was no statistically significant correlation between the serum PRL and LH or FSH levels in the microprolactinoma patients. We conclude that LHRH agonists can counteract the hyperprolactinemia produced by microprolactinomas and that the effect probably is not exerted by an action on the gonadotrophs.

UR - http://www.scopus.com/inward/record.url?scp=0024344908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024344908&partnerID=8YFLogxK

M3 - Article

C2 - 2526819

AN - SCOPUS:0024344908

VL - 69

SP - 444

EP - 447

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -